Inozyme Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Inozyme Pharma has a total shareholder equity of $118.8M and total debt of $45.0M, which brings its debt-to-equity ratio to 37.9%. Its total assets and total liabilities are $176.9M and $58.1M respectively.
Key information
37.9%
Debt to equity ratio
US$45.03m
Debt
| Interest coverage ratio | n/a |
| Cash | US$166.15m |
| Equity | US$118.84m |
| Total liabilities | US$58.11m |
| Total assets | US$176.94m |
Recent financial health updates
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11
Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Recent updates
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Financial Position Analysis
Short Term Liabilities: INZY's short term assets ($174.3M) exceed its short term liabilities ($12.4M).
Long Term Liabilities: INZY's short term assets ($174.3M) exceed its long term liabilities ($45.7M).
Debt to Equity History and Analysis
Debt Level: INZY has more cash than its total debt.
Reducing Debt: INZY's debt to equity ratio has increased from 0% to 37.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INZY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INZY has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 27.4% each year.